An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma

Trial Profile

An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Osteosarcoma; Soft tissue sarcoma
  • Focus Pharmacokinetics
  • Sponsors Karyopharm Therapeutics; NPM Pharma
  • Most Recent Events

    • 31 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 19 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
    • 19 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top